Cytomegalovirus related hospitalization costs among hematopoietic stem cell and solid organ transplant recipients treated with maribavir versus investigator‐assigned therapy: A US‐based study
Transplant Infectious Disease · 2024
DOI: 10.1111/tid.14216 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transplant Infectious Disease, 2024. Verfasst von Bob G Schultz und 3 weiteren Autor:innen. Beteiligte Einrichtung: US Medical Affairs Outcomes Research, Takeda Pharmaceuticals U.S.A., Inc., Lexington, Massachusetts, USA. Hauptthemen laut MEDLINE: Cytomegalovirus Infections, Ribonucleosides, Organ Transplantation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Takeda Pharmaceuticals U.S.A..
Abstract (Originalsprache)
Background
Cytomegalovirus (CMV) infections among hematopoietic stem cell transplant (HSCT) and solid organ transplant (SOT) recipients impose a significant health care resource utilization (HCRU)‐related economic burden. Maribavir (MBV), a novel anti‐viral therapy (AVT), approved by the United States Food and Drug Administration for post‐transplant CMV infections refractory (with/without resistance) to conventional AVTs has demonstrated lower hospital length of stay (LOS) versus investigator‐assigned therapy (IAT; valgancilovir, ganciclovir, foscarnet, or cidofovir) in a phase 3 trial (SOLSTICE). This study estimated the HCRU costs of MBV versus IAT.
Methods
An economic model was developed to estimate HCRU costs for patients treated with MBV or IAT. Mean per‐patient‐per‐year (PPPY) HCRU costs were calculated using (i) annualized mean hospital LOS in SOLSTICE, and (ii) CMV‐related direct costs from published literature. Probabilistic sensitivity analysis with Monte‐Carlo simulations assessed model robustness.
Results
Of 352 randomized patients receiving MBV ( n = 235) or IAT ( n = 117) for 8 weeks in SOLSTICE, 40% had HSCT and 60% had SOT. Mean overall PPPY HCRU costs of overall hospital‐LOS were $67,205 (95% confidence interval [CI]: $33,767, $231,275) versus $145,501 (95% CI: $62,064, $589,505) for MBV and IAT groups, respectively. Mean PPPY ICU and non‐ICU stay costs were: $32,231 (95% CI: $5,248, $184,524) versus $45,307 (95% CI: $3,957, $481,740) for MBV and IAT groups, and $82,237 (95% CI: $40,397, $156,945) MBV versus $228,329 (95% CI: $94,442, $517,476) for MBV and IAT groups, respectively. MBV demonstrated cost savings in over 99.99% of simulations.
Conclusions
This analysis suggests that Mean PPPY HCRU costs were 29%–64% lower with MBV versus other‐AVTs. image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- US Medical Affairs Outcomes Research, Takeda Pharmaceuticals U.S.A., Inc., Lexington, Massachusetts, USA.
- Health Economics and Outcomes Research, Anlitiks, Inc., Windermere, Florida, USA.
ORCID-Profile: Deepika Paratane
Förderung
- Takeda Pharmaceuticals U.S.A.
Zitieren
APA
Schultz, B. G., Bullano, M., Paratane, D., & Rajagopalan, K. (2024). Cytomegalovirus related hospitalization costs among hematopoietic stem cell and solid organ transplant recipients treated with maribavir versus investigator‐assigned therapy: A US‐based study. Transplant Infectious Disease. https://doi.org/10.1111/tid.14216
Vancouver
Schultz BG, Bullano M, Paratane D, Rajagopalan K. Cytomegalovirus related hospitalization costs among hematopoietic stem cell and solid organ transplant recipients treated with maribavir versus investigator‐assigned therapy: A US‐based study. Transplant Infectious Disease. 2024. doi:10.1111/tid.14216
BibTeX
@article{Schultz2024,
author = {Schultz, Bob G and Bullano, Michael and Paratane, Deepika and Rajagopalan, Krithika},
title = {Cytomegalovirus related hospitalization costs among hematopoietic stem cell and solid organ transplant recipients treated with maribavir versus investigator‐assigned therapy: A US‐based study},
journal = {Transplant Infectious Disease},
year = {2024},
doi = {10.1111/tid.14216}
}
EUVIMED